Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IOVA | Iovance Biotherapeutics, Inc.

Index	RUT	P/E	-	EPS (ttm)	-2.25	Insider Own	0.10%	Shs Outstand	247.78M	Perf Week	-6.55%
Market Cap	1.08B	Forward P/E	-	EPS next Y	-1.43	Insider Trans	-	Shs Float	232.91M	Perf Month	-21.95%
Income	-418.80M	PEG	-	EPS next Q	-0.45	Inst Own	91.41%	Short Float / Ratio	12.91% / 4.96	Perf Quarter	-38.97%
Sales	0.20M	P/S	5377.85	EPS this Y	-11.40%	Inst Trans	-2.38%	Short Interest	30.07M	Perf Half Y	-14.35%
Book/sh	2.58	P/B	1.91	EPS next Y	24.50%	ROA	-60.00%	Target Price	22.36	Perf Year	-50.90%
Cash/sh	1.15	P/C	4.29	EPS next 5Y	-	ROE	-78.30%	52W Range	4.41 - 10.41	Perf YTD	-22.93%
Dividend	-	P/FCF	-	EPS past 5Y	-12.00%	ROI	-	52W High	-52.69%	Beta	0.13
Dividend %	-	Quick Ratio	3.00	Sales past 5Y	-	Gross Margin	-	52W Low	11.68%	ATR	0.47
Employees	503	Current Ratio	3.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.35	Volatility	10.87% 7.15%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	24.90%	Profit Margin	-	Rel Volume	0.77	Prev Close	5.03
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 08 AMC	Payout	-	Avg Volume	6.06M	Price	4.93
Recom	1.80	SMA20	-14.78%	SMA50	-25.61%	SMA200	-28.61%	Volume	2,726,776	Change	-2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-23	Reiterated	Barclays	Overweight	$40 → $18
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$11 → $17
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$11
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$11 → $14
Dec-09-22	Downgrade	Goldman	Buy → Neutral	$20 → $6
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight	$14
Jan-28-22	Upgrade	Stifel	Hold → Buy	$23 → $25
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$32
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$35 → $18
May-19-21	Downgrade	Stifel	Buy → Hold
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-03-21	Initiated	Truist	Buy	$50
Apr-16-21	Initiated	Goldman	Buy	$97
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy	$50
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy	$61
Mar-04-20	Initiated	Barclays	Overweight	$45

Show Previous Ratings

Sep-15-23 04:20PM	Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today (Motley Fool) +13.46%
07:26AM	Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug (Zacks)
Sep-14-23 06:10PM	U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma (GlobeNewswire) -14.54%
04:36PM	Why Shares of Iovance Biotherapeutics Dropped Thursday (Motley Fool)
Sep-07-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report? (Zacks)
07:31AM	Loading…
07:31AM	Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey)
Aug-28-23 11:53PM	3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List (InvestorPlace)
Aug-18-23 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-09-23 11:14AM	Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2 (Zacks) +6.44%
Aug-08-23 05:50PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:50PM	Iovance Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates (GlobeNewswire)
Jul-31-23 06:10AM	7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick (InvestorPlace)
Jul-25-23 04:01PM	Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
04:01PM	Loading…
Jul-24-23 04:01PM	Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023 (GlobeNewswire)
Jul-21-23 05:34PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-13-23 04:01PM	Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering (GlobeNewswire)
Jul-11-23 04:30PM	These Stocks Are Moving the Most Today: Activision, Amazon, WD-40, Affirm, Shutterstock, and More (Barrons.com) -9.78%
11:18AM	Why Iovance Biotherapeutics Stock Is Dropping Tuesday (Motley Fool)
10:53AM	Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug (Zacks)
09:26AM	Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning (Motley Fool)
04:56AM	Iovance Biotherapeutics slips after $150 million stock offering price announced (Investing.com)
Jul-10-23 09:46PM	Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock (GlobeNewswire) +21.41%
04:34PM	Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:00AM	Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer (GlobeNewswire)
Jun-24-23 03:19PM	11 Best Medical Stocks Under $10 (Insider Monkey)
Jun-20-23 07:01AM	Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape (GlobeNewswire)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks) -6.02%
Jun-15-23 07:01AM	Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma (GlobeNewswire)
07:01AM	Loading…
Jun-09-23 07:01AM	Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
Jun-08-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report? (Zacks)
May-30-23 04:18PM	Why Shares of Iovance Biotherapeutics Jumped Tuesday (Motley Fool) +17.22%
04:18PM	These Stocks Moved the Most Today: Nvidia, Marvell, C3.ai, Palantir, and More (Barrons.com)
01:54PM	These Stocks Are Moving the Most Today: Nvidia, Marvell, C3.ai, Palantir, and More (Barrons.com)
May-29-23 10:08AM	FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug (Zacks)
May-26-23 05:30PM	Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma (GlobeNewswire)
May-24-23 12:03PM	A US$352m Market Cap Boost Pleasing ToIovance Biotherapeutics Insiders \ (Simply Wall St.) -10.93%
May-16-23 09:25AM	Billionaire Steve Cohen Snaps Up These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks)
May-11-23 01:40PM	Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 12:16PM	Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1 (Zacks)
May-09-23 04:01PM	Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-02-23 04:01PM	Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023 (GlobeNewswire)
May-01-23 04:00PM	Why Shares of Iovance Biotherapeutics Jumped Monday (Motley Fool) +14.01%
Apr-24-23 07:01AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Apr-20-23 09:45AM	Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon (Motley Fool)
Apr-06-23 07:22AM	Should You Hold Iovance Biotherapeutics (IOVA)? (Insider Monkey)
Mar-30-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report? (Zacks) -7.24%
Mar-27-23 03:56PM	Why Shares of Iovance Biotherapeutics Jumped Monday (Motley Fool) +11.21%
11:35AM	Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug (Zacks)
Mar-24-23 04:01PM	Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma (GlobeNewswire)
Mar-21-23 05:10PM	12 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-04-23 08:13AM	Great week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) institutional investors after losing 43% over the previous year (Simply Wall St.)
Mar-02-23 09:17PM	Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 12:33PM	Q4 2022 Iovance Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:04AM	Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil (Zacks)
08:03AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Feb-28-23 04:01PM	Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates (GlobeNewswire)
Feb-27-23 09:31AM	Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More (Zacks)
Feb-21-23 04:01PM	Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023 (GlobeNewswire)
Jan-24-23 12:15PM	Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6% (Zacks) +9.86%
Jan-23-23 06:37PM	Why Iovance Biotherapeutics Stock Soared 12% Higher Today (Motley Fool) +11.64%
11:39AM	Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M (Benzinga)
08:00AM	Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates (GlobeNewswire)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Dec-11-22 07:23AM	Trade Alert: The Independent Director Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), Wayne Rothbaum, Has Just Spent US$65m Buying 124% More Shares (Simply Wall St.)
Nov-30-22 07:00AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Nov-21-22 12:11PM	Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug (Zacks)
Nov-18-22 01:06PM	Why Iovance Biotherapeutics Is Crashing Today (Motley Fool) -6.76%
12:09PM	Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate (Benzinga)
09:00AM	Iovance's stock is down after receiving FDA feedback on application for new melanoma drug (MarketWatch)
06:30AM	Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma (GlobeNewswire)
Nov-12-22 08:34AM	Bullish insiders at Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) loaded up on US$6.9m of stock earlier this year (Simply Wall St.)
Nov-10-22 12:33PM	Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +10.59%
Nov-07-22 08:01AM	Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -7.75%
Nov-04-22 12:31PM	Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil (Zacks)
Nov-03-22 04:01PM	Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates (GlobeNewswire)
Oct-27-22 07:19PM	11 Best Very Cheap Stocks To Buy Now According To Hedge Funds (Insider Monkey)
Oct-24-22 04:01PM	Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022 (GlobeNewswire)
Oct-11-22 11:49AM	Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study (Zacks)
Oct-10-22 07:30AM	Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy (GlobeNewswire) -11.46%
Oct-05-22 09:45AM	Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy (Zacks)
08:05AM	Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-12-22 07:00AM	Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer (GlobeNewswire)
Sep-06-22 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) -8.74%
09:00AM	Iovance Biotherapeutics to Present Posters at ESMO 2022 (GlobeNewswire)
Aug-26-22 01:13PM	Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy (Zacks) -5.90%
Aug-25-22 01:05PM	Biomedical technician training program launches to support Philadelphia's growing life sciences sector (American City Business Journals)
07:30AM	Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma (GlobeNewswire)
Aug-05-22 12:13PM	Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track (Zacks)
Aug-04-22 04:01PM	Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates (GlobeNewswire)
Jul-27-22 07:00AM	Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022 (GlobeNewswire)
Jul-22-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.91%
Jun-22-22 10:48AM	Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs (Zacks) +7.29%
Jun-17-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.75%
Jun-13-22 04:01PM	Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors (GlobeNewswire) -7.47%
Jun-12-22 09:00AM	Five Beaten-Up Biotech Stocks Saw Big Share Purchases (Barrons.com)
Jun-08-22 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) +9.86%
Jun-06-22 08:34PM	Down More Than 40%: Insiders Call a Bottom in These 2 Stocks (TipRanks)
Jun-05-22 09:06AM	Wayne Rothbaum Is The Independent Director of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) And They Just Picked Up 14% More Shares (Simply Wall St.)

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universite de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCPEAK MERRILL A	Director	Sep 18	Buy	5.56	10,000	55,600	248,633	Sep 19 04:30 PM
Rothbaum Wayne P.	Director	Sep 15	Buy	5.30	5,000,000	26,500,000	23,067,333	Sep 15 06:12 PM
BILINSKY IGOR	Chief Operating Officer	Jul 14	Option Exercise	0.00	2,813	0	28,608	Jul 17 06:21 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jul 14	Option Exercise	0.00	2,813	0	32,348	Jul 17 06:22 PM
Vogt Frederick G	Interim CEO & General Counsel	Jul 14	Option Exercise	0.00	20,834	0	81,701	Jul 17 06:22 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Apr 14	Option Exercise	0.00	2,812	0	30,930	Apr 18 05:49 PM
Vogt Frederick G	Interim CEO & General Counsel	Apr 14	Option Exercise	0.00	20,834	0	69,718	Apr 18 05:50 PM
BILINSKY IGOR	Chief Operating Officer	Apr 14	Option Exercise	0.00	2,812	0	27,190	Apr 18 05:48 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jan 17	Option Exercise	0.00	11,248	0	32,796	Jan 19 04:52 PM
BILINSKY IGOR	Chief Operating Officer	Jan 17	Option Exercise	0.00	11,248	0	29,049	Jan 19 04:52 PM
Vogt Frederick G	Interim CEO & General Counsel	Jan 17	Option Exercise	0.00	83,325	0	85,325	Jan 19 04:51 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jan 03	Option Exercise	0.00	19,690	0	32,571	Jan 05 08:57 PM
BILINSKY IGOR	Chief Operating Officer	Jan 03	Option Exercise	0.00	18,850	0	28,354	Jan 05 08:45 PM
Bellemin Jean-Marc	Chief Financial Officer	Jan 03	Option Exercise	0.00	18,850	0	28,354	Jan 05 08:45 PM
MCPEAK MERRILL A	Director	Dec 21	Buy	6.15	10,000	61,500	70,150	Dec 22 04:06 PM
Rothbaum Wayne P.	Director	Dec 02	Buy	6.50	10,000,000	65,000,000	18,067,333	Dec 02 05:29 PM
MCPEAK MERRILL A	Director	Nov 29	Buy	6.31	10,000	63,100	238,633	Nov 30 04:17 PM
MCPEAK MERRILL A	Director	Nov 28	Buy	6.18	10,000	61,800	228,633	Nov 28 09:44 PM
Vogt Frederick G	Interim CEO & General Counsel	Nov 28	Buy	5.98	1,000	5,980	2,000	Nov 28 09:46 PM
Dukes Iain D.	Director	Nov 23	Buy	6.10	10,000	61,000	22,000	Nov 28 09:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOVA | Iovance Biotherapeutics, Inc.

Upgrade your FINVIZ experience